I et akut myokardieinfarkt- studie syntes eptifibatid imidlertid at øge risikoen for blødning ved indgift med streptokinase.
There was no consistent evidence that eptifibatide increased the risk of major or minor bleeding associated with tissue plasminogen activator in either a PCI or an acute myocardial infarction study; however, eptifibatide appeared to increase the risk of bleeding when administered with streptokinase in an acute myocardial infarction study.